Objectives To assess the ability of different technology platforms to detect epidermal growth
factor receptor (EGFR) mutations, including T790M, from circulating tumor DNA (ctDNA) in …

Cancer treatment is evolving towards therapies targeted at specific molecular abnormalities
that drive tumor growth. Consequently, to determine which patients are eligible, accurate …

Abstract Analysis of circulating tumor DNA (ctDNA) is emerging as a powerful tool for
guiding targeted therapy and monitoring tumor evolution in patients with non-small cell lung …

Introduction To offer patients with EGFR mutation–positive advanced NSCLC appropriate
EGFR tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required …

A sensitive and convenient method for detecting epidermal growth factor receptor (EGFR)
T790M mutations from circulating tumor DNA (ct DNA) in advanced non–small cell lung …

Introduction Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive,
costly, and not always feasible for patients with late-stage disease. The clinical utility of the …

Abstract EGFR T790M mutation occurs in half of non-small cell lung cancer (NSCLC)
patients with acquired EGFR-TKI (TKI) resistance, based on tumor re-biopsies using an …

Background This study assesses different technologies for detecting epidermal growth factor
receptor (EGFR) mutations from circulating tumor DNA in patients with EGFR T790M …

Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …

Purpose The purpose of this meta-analysis was to explore the influences of pretreatment de
novo and posttreatment-acquired epidermal growth factor receptor (EGFR) T790M mutations …